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Acute kidney injury (AKI) is one of the most relevant health issues, leading to millions of deaths. The
magnitude of the phenomenon remarks the urgent need for innovative and effective therapeutic
approaches. Cell-based therapy with renal progenitor cells (RPCs) has been proposed as a possible strategy.
Studies have shown the feasibility of directing embryonic stem cells or induced Pluripotent Stem Cells
(iPSCs) towards nephrogenic intermediate mesoderm and metanephric mesenchyme (MM). However, the
functional activity of iPSC-derived RPCs has not been tested in animal models of kidney disease. Here,
through an efficient inductive protocol, we directed human iPSCs towardsRPCs that robustly engrafted into
damaged tubuli and restored renal function and structure in cisplatin-mice with AKI. These results
demonstrate that iPSCs are a valuable source of engraftable cells with regenerative activity for kidney disease
and create the basis for future applications in stem cell-based therapy.
A
cute kidney injury (AKI) is an important cause of morbidity andmortality worldwide affecting more than
13million people, especially in poor resource countries1,2. Here, AKI is generally a disease of young adults
and children who continue to die as a consequence of this disorder because renal replacement therapy is
not available. Therefore the development of new strategies directed to support and improve renal function is
greatly demanded. One promising approach aimed at kidney regeneration is cell-based therapy that requires the
availability of cells able to efficiently replace cellular components of the diverse renal compartments. Studies have
suggested renal progenitors, isolated from adult tissue3–6, as a possible option, although their clinical translation is
limited by the inaccessibility of the cell-source in patients, poor expansion capability and restricted differentiation
potential. iPSCs, pluripotent cells that possess extensive self-renewal capacity, offer the possibility of patient-
specific treatments and may represent a cell type worth investigation for therapy. Undifferentiated murine iPSCs
have been described to attenuate kidney injury in ischemia reperfusion-induced AKI only when administered via
intra-arterial route, by paracrine action7. However, the pluripotent nature of iPSCs raise concerns on high risk of
tumour development when these cells are administered without pre-differentiation. An attractive alternative
consists in the derivation of renal progenitors from iPSCs. Initial approaches with murine embryonic stem cells
(ESCs) and iPSCs have shown the feasibility to generate cells expressing intermediate mesoderm (IM) and MM
markers8–22 by exposure to specific factors including Activin A and retinoic acid (RA) in combination with bone
morphogenic proteins (BMPs) or GDNF, important factors in kidney development23. Recently, human ESCs and
iPSCs have been described to differentiate into nephrogenic cells, renal proximal tubular and podocyte
lineages16–22,24. However, robust engraftment of human iPSC-derived RPCs in an animal model of AKI associated
with restoration of kidney function and structure has never been shown.
Results
Here, we report an efficient and reproducible two-stage protocol to obtain renal progenitors from human iPSCs
(Fig. 1a). Initially, we performed differentiation studies on commercially available iPSCs obtained from human
foreskin fibroblasts transfected with retrovirus encoding for Oct4, Sox2, Klf4, and c-Myc. In stage 1, to induce
differentiation towardmesoderm (ME) and IM-like cells, we exposed undifferentiated iPSCs for 6 days to RA and
OPEN
SUBJECT AREAS:
PLURIPOTENT STEM CELLS
REPROGRAMMING
Received
15 September 2014
Accepted
5 February 2015
Published
6 March 2015
Correspondence and
requests for materials
should be addressed to
A.B. (ariela.benigni@
marionegri.it)
* These authors
contributed equally to
this work.
SCIENTIFIC REPORTS | 5 : 8826 | DOI: 10.1038/srep08826 1
to the small molecules RhoA inhibitor (CCG1423) and PI3K inhib-
itor (LY294002). The employment of small molecules has been sug-
gested as a simple and direct method to address stem cell
differentiation22,25. Activin A, known to stimulate the expression of
IM markers in ESCs8,14, was added for two days starting on day 2. In
stage 2, by day 6 up to 19, iPSCs were exposed to a cocktail of three
nephrogenic factors FGF2, BMP7 and GDNF to commit cells
towards MM. Undifferentiated iPSCs expressed pluripotency mar-
kers SSEA4, TRA-1-81, and Nanog (Fig. 1b) that progressively
decreased after exposure to stage 1-medium. SSEA4 and TRA-1-81
were almost completely absent on day 6 whereas only few cells
expressed a weak Nanog staining (Fig. 1b). By cytofluorimetric ana-
lysis, when we analyzed undifferentiated iPSCs, we found that the
mean percentage of cells expressing TRA-1-81 was 88.5% 6 0.9
whereas it decreased at 24.7% 6 1.39 and 22.2% 6 0.93 respectively
on day 12 and 19 of differentiation, exhibiting a very low fluorescence
intensity per cell. As early as 3 days, we detected the expression of T
(Brachyury), a transient marker of ME, that decreased on day 6 to a
faint signal (Fig. 1b). Osr1, one of the earliest transcription factors
specifying a multipotent population of IM cells giving rise to MM
cells26, increased after 3 days and progressively decreased at 6 days
(Fig. 1b). Other IM-specific markers including Wt1, Pax8 and Pax2
were observed by day 6 (Fig. 1c). At the same time, we found initial
expression of Six2 and Sall1 (Fig. 1c) indicating the establishment of
precursorMM fate. As a result of the exposure to stage 2-medium, on
day 12 we found stable expression ofWt1, Pax8, Pax2, Six2 and Sall1
that decreased on day 19 except for Sall1 that maintained high
expression. The developmental progression towards renal progenitor
phenotype was confirmed by the presence of specific markers such as
NCAM, CD133 and CD24 that during differentiation acquired cel-
lular-specific localization. NCAM, normally expressed in the
nephrogenic zone of developing kidney27 was induced by day 12
showing a clear pattern of expression at the cell periphery
(Fig. 1d). CD133 and CD24, markers found in MM cells and glom-
erular progenitor cells28,29, were expressed on almost all the cells at
any differentiation time considered (Fig. 1d) however, their distri-
bution changed from a punctuated staining in undifferentiated iPSCs
to a characteristic well-organized peripheral pattern by day 12
(Fig. 1d). Finally, we characterized the expression of Claudin1, a
marker of glomerular epithelial cells and Aquaporin 1 (AQP1) and
gamma-glutamyl transferase 1 (GGT1) markers of proximal tubular
cells. By day 12, we observed a weak induction of Claudin1 and an
Figure 1 | Stepwise differentiation of human iPSCs towards renal progenitor cells (RPCs). (a) Schematic description of the two-stage protocol applied
to iPSC-renal commitment. (b, c, d, e) Immunofluorescence of iPSCs (derived from retroviral transfected dermal fibroblasts) exposed to
differentiating media. (b) The pluripotency markers SSEA4, TRA-1-81, Nanog, ME marker T(Bry) and IM marker Osr1. (c) IM and MM marker
expression asWt1, Pax8, Pax2, Six2 and Sall1. (d) Renal progenitor markers CD133, CD24, NCAM, glomerular epithelial marker Claudin1 and proximal
tubular epithelial markers AQP1, GGT1. (e) Markers identifying endodermal AFP, ectodermal Pax6, and cardiac mesodermal Nkx2.5 derivation. Nuclei
are stained with DAPI (blue). Scale bars: 20 mm (b, c, d, e).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8826 | DOI: 10.1038/srep08826 2
intenseAQP1 staining (Fig. 1d) whereas GGT1wasweakly expressed
on day 19 (Fig. 1d). Differentiated iPSCs did not express alpha-feto-
protein (AFP), Pax6 and Nkx2.5, markers of endoderm, neuroecto-
derm and cardiac mesoderm, respectively (Fig. 1e).
Next, we tested the robustness of the two-step differentiation pro-
tocol on iPSCs generated in our laboratory by reprogramming
human fibroblasts using the STEMCCA Cre-excisable polycistronic
lentivirus with excisable reprogramming cassette. Specifically, the
generated iPSC clones showed all the properties of the pluripotent
stem cells in terms of expression of pluripotency markers, karyotype
and ability to differentiate both in vitro and in vivo into derivatives of
the three germ layers (Supplementary Fig. 1a-f). The fully character-
ized clone IV was used to test the differentiation protocol.
Immunofluorescence analysis showed a pattern of protein express-
ion similar to that observed with commercial iPSCs. Indeed, down-
regulation of the pluripotency marker Nanog was observed going
from undifferentiated cells to day 6 of differentiation. Conversely,
upregulation of markers specific to the early ME, which included T,
for the IM such as Lhx1, Osr1 (Supplementary Fig. 2a) and laterWt1,
Pax8 and Pax2, and for the MM such as Six2 and Sall1 was detected
(Supplementary Fig. 2b). To better define the phenotype of iPS clone
IV-derived RPCs, we evaluated the co-expression of several markers
which defines renal commitment. Our data show the specification
into a homogeneous IM cell population from day 3 to 6 as demon-
strated by Lhx1/Osr1 co-expression (Fig. 2a). Six2 co-staining with
Pax2, Pax8 andWt1 at day 6 and 12 confirms differentiation toward
MM cell phenotype (Fig. 2b). Protein expression of CD24 - already
present in undifferentiated cells - Claudin1 and GGT1 was evident
throughout the differentiation protocol (Fig. 2c).We next performed
gene expression analysis by real-time PCR and found that the
expression of gene and corresponding protein paralleled over time
(Fig. 2d). Collectively, our results demonstrate that the protocol we
established supports the efficient commitment of the two different
human iPSC cell lines towards RPCs and provides the basis for
functional studies.
The derivation of RPCs from iPSCs offers new platforms for drug
screening and for in vitro tissue engineering however, the major
challenge resides on their employment in regenerative medicine to
in vivo generate new functional cells. Therefore, we next assessed the
renoprotective potential of human iPSC-derived RPCs, obtained on
day 12, in the murine model of cisplatin-induced AKI which is char-
acterized by severely compromised renal function and tubular
damage 4 days after drug injection30. Intravenously infused iPSC-
derived RPCs were found in the kidney as early as 24 h. At 4 days, a
sustained number of iPSC-derived RPCs was observed in the cortical
region of the kidney of cisplatin mice as proved by the presence of
human mitochondria (h-Mito), human nuclear antigen (HNA) or
PKH26 cell tracker (Fig. 3a and b). Human cells were found inte-
grated into murine tubuli identified by wheat germ agglutinin
(WGA)-lectin staining and cortical areas showed extensive engraft-
ment accounting for 42% 6 12 HNA positive cells per high power
field (HPF). By immunofluorescence staining with AQP1, we pro-
vided evidence that human PKH26 positive iPSC-derived RPCs
mainly engrafted in proximal tubuli and expressed a marker of prox-
Figure 2 | Differentiation of human iPSC clone IV towards renal commitment. (a) Representative immunofluorescence images of co-staining for
Lhx1/Osr1 up to day 6. (b) Images of co-staining of Pax2/Six2, Pax8/Six2 and Six2/Wt1 from day 6 to 12. (c) Expression of renal progenitor markers
such as CD24, Claudin1 andGGT1 fromday 0 to 19.Nuclei are stainedwithDAPI (blue). Scale bars: 50 mm(a, b), 20 mm(c). (d)Gene expression analysis
for renal progenitor markers at different points in time.
www.nature.com/scientificreports
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imal tubular cells (Fig. 3b, left). This result was confirmed by immu-
noperoxidase technique showing the co-localization of the signal for
human mitochondria and AQP1 in proximal tubular cells (Fig. 3b,
central and right panels). No human iPSC-derived RPCs were found
in peanut agglutinin (PNA)-lectin positive distal tubuli while scat-
tered human cells were observed in AQP3-positive collecting ducts.
Engrafted human iPSC-derived RPCs, co-stained for the prolifera-
tion marker Ki-67 and HNA, showed 30% of human cells prolif-
erating in proximal tubuli (Supplementary Fig. 3). Tropism of
transplanted human cells for the kidney was supported by the obser-
vation that a paltry number of engrafted cells was found in other
organs including liver (0.26 0.07 cells/HPF), lung (0.266 0.06 cells/
HPF), heart (0.22 6 0.08 cells/HPF) and spleen (0.16 6 0.06 cells/
HPF) 24 h after cell infusion (Supplementary Fig. 4) while no human
cells were found at 4 days in all the organs studied. Mice that experi-
enced renal engraftment exhibited a significant improvement of
renal function to the extent of a 55% reduction of blood urea nitrogen
(BUN) levels as compared with cisplatin-treated mice given saline
(Fig. 3c). Renal histology of mice receiving human iPSC-derived
RPCs was significantly improved, as shown by the remarkable reduc-
tion of renal tubular damage in terms of cell swelling, cast deposition,
loss of brush border and cell necrosis compared to mice receiving
saline (Fig. 3d). Proliferation of tubular cells, assessed by Ki-67
expression, was increased primarily in the proximity of engrafted
human cells compared to cisplatin mice given saline (Ki-67 positive
cells/HPF: iPSC-derived RPCs, 14 6 0.86 vs saline, 8 6 0.06; p ,
0.01).
Injection of human undifferentiated iPSCs, here used as control,
failed to exert any protective effect on renal function (Fig. 3c) and
renal histology (Fig. 3d). Undifferentiated iPSCs were not present in
the kidney and in the other organs at both 24 h and 4 days after
cisplatin injection. No signs of inappropriate differentiation and
tumor formation by iPSC-derived RPCs were noted in the renal
tissues either at 4 days or 8 weeks after cisplatin injection.
Herein, we defined a successful differentiation protocol to effi-
ciently derive renal progenitor cells fromhuman iPSCs that consisted
of the exposure of the cells to specific small molecules and growth
factors resulting in the acquisition of markers sequentially expressed
in different phases of kidney development. During the first stage of
the differentiation process, we obtained a cell population with wide-
spread expression of IMmarkers, whereas later on cells acquiredMM
phenotype consistent with the presence of early renal progenitor cells
Figure 3 | Human iPSC-derived RPC regenerative potential in experimental AKI. (a) Human iPSC-derived RPCs identified in mice with cisplatin-
induced AKI by human mitochondrial (h-Mito) staining (red) or HNA staining (green). Scale bars: 10 mm. (b) Human iPSC-derived RPCs,
pre-labelled with PKH26 cell tracker (red, arrows) identified in cisplatin mice, express AQP1 (white, left panels). Immunoperoxidase staining of renal
sections of cisplatin mice receiving saline or iPSC-derived RPCs (serial sections) labelled with h-Mito or AQP1 antibody (central and right panels). In
serial sections, the areas encircled by a black line represent the same tubule. Human kidney section is shown as positive control for h-Mito staining. Scale
bars: 20 mm. (c) Renal function expressed as blood urea nitrogen (BUN) inmicewith cisplatin inducedAKI given saline, undifferentiated iPS cells (iPSCs)
or iPSC-derived RPCs at 4 days (mean6 SEM, n5 5, *p, 0.01 versus Control; up, 0.01 vs cisplatin plus saline or iPSCs). (d) Histological evaluation of
kidney samples from control, cisplatin mice receiving saline, undifferentiated iPS cells or iPSC-derived RPCs, 4 days after cisplatin (mean 6 SEM, n 5 5,
*p , 0.01 versus Control; up , 0.01 vs cisplatin plus saline or iPSCs). Scale bars: 50 mm.
www.nature.com/scientificreports
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and also expressed markers such as NCAM and CD24 in a special-
ized cell-cell contact distribution. This achievement represents a new
platform to push the research of patient-specific pluripotent stem
cells toward the generation of renal tissues. The capacity of human
iPSC-derived RPCs to exert renoprective effects has been proved here
in a murine model of AKI. The intravenous cell administration is
compatible with possible future extension of this approach to human
patients. Moreover, we have additionally found that iPSC-derived
RPCs extensively engraft damaged tubuli, proliferate and promote
proliferation of adjacent resident tubular cells, acquire tubular epi-
thelial phenotype and improve renal function and tubular injury.
Whether the reparative properties of human iPSC-derived RPCs
are dependent on direct incorporation into damaged renal structure
or via the activation of tubular cell proliferation is open to specu-
lation. Although efforts must ensue for successful translation to
patients, this knowledge points the way for the treatment of kidney
diseases by means of stem cell-based technologies and fulfills the
promise of the therapeutic value of iPSCs. The successful generation
of patient-specific iPSC-derived renal progenitors will enable diverse
biomedical applications including developmental studies, high-
throughput drug discovery as well as providing physiologically rel-
evant cells for disease modelling.
Methods
Cell culture.Commercially available human iPSCs (SC101A-1) were purchased from
SystemBiosciences International andmaintained in DMEM/F12medium containing
20% Knockout Serum Replacement (Invitrogen), 0.1 mM nonessential amino acids
(Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma), 10 ng/ml human basic fibroblast
growth factor (FGF2, PeproTech) and 1% penicillin and streptomycin. Mouse
embryonic fibroblasts (MEFs), used as feeder cells for iPSCs, were isolated from
embryos of 13.5 days (E13.5) from CD1 mice and cultured in DMEM medium
containing 10% FBS (Invitrogen), 0.1 mMnonessential amino acids (Invitrogen) and
1% penicillin and streptomycin. For passaging, human iPSCs were incubated with
accutase (Millipore). Cell suspension was seeded on mitomycin C-inactivated MEFs
in the presence of Rock inhibitor (Sigma). Human dermal neonatal fibroblast cells
(NHDF- Neo) were purchased from Lonza and were maintained in MEM medium
supplemented with 10% FBS (Lonza), 2 mMGlutamine (Invitrogen), 1 mM Sodium
Pyruvate (Invitrogen) and 1% penicillin and streptomycin.
Derivation and characterization of human iPS clone IV. Generation of human iPS
cell line. Human iPSCs were derived from human dermal neonatal fibroblasts by
STEMCCA Cre-Excisable Constitutive Polycistronic (OKMS) lentivirus (Millipore)
following manufacturer’s instructions. Briefly, a total of 25,000 human neonatal
fibroblasts were plated on a plastic 35-mm culture plate. The next day cells were
infected with 200 MOI of virus in human fibroblast medium in the presence of
polybrene (5 mg/ml). The medium was replaced 24 hours after transduction with
fresh virus-containing medium for a second cycle of infection. Six days after the first
infection fibroblasts were trypsinized and plated at different densities onMEF-feeder
coated dishes (eg. 20,000 or 50,000 per 10-cm culture dish). The next day themedium
was changed to human iPSC-medium. The medium was changed every other day
until the first colonies started to appear and then every day. iPSC colonies were
manually picked about 30 days post-infection, transferred into 0.5 ml of human
iPSC-medium and dissected to small clumps by pipetting and seeded onto a new
MEFs feeder in a well of six well-plate. The colonies were mechanically split for 3
passages and then cultured as described above. Clone IV has been chosen for
characterization and differentiation studies.
Karyotyping. Metaphase spreads were prepared after treatment with 10 mg/ml
Colcemid and processed for karyotype analysis. At least 20metaphases of each sample
were counted. Karyotype analysis was performed in collaboration with the Genetic
Medicine Laboratory of Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (Italy).
Embryoid body (EB) formation. For EB formation, human iPSCs clone IV were
harvested by treating with DMEM/F12 containing 1 mg/ml collagenase IV at 37uC.
When the perimeter of the colonies appeared highlighted and the cells started to peel
up collagenase was removed and the colonies were scraped in human iPSCs medium
and centrifuged. The clumps of the cells were suspended and cultured in DMEM/F12
medium supplemented with 20% Knockout serum replacement, 0.1 mM nonessen-
tial amino acids, 0.1 mM2-mercaptoethanol and 1%penicillin and streptomycin and
then transferred to low attachment dish. The medium was replaced every other day.
After 8 days as floating culture, EBs were transferred onto gelatin-coated plate and
cultured in the same medium for another 8 days. At day sixteen the plates were fixed
with 4% PFA solution and processed by immunostaining.
Teratoma formation and analysis. Undifferentiated human iPS clone IV (106/site)
were injected subcutaneously into dorsal flank of NOD-SCID mice (n 5 3). Eight
weeks after injection, teratomas were dissected, fixed in formalin, embedded in
paraffin and stained for hematoxylin and eosin.
Human iPSC differentiation into renal progenitor cells. To induce differentiation
toward mesoderm (ME) and intermediate mesoderm (IM)-like cells human iPSC-
growth medium was replaced with basal DMEM/F12 medium containing 5% FBS
(Hyclone), 0.1 mM nonessential amino acids, 0.1 mM 2- mercaptoethanol
supplemented with 0.1 mMAll-Trans Retinoic Acid (Sigma), 1 mMCCG1423 (RhoA
Inhibitor, Vinci Biochem) and 5 mM LY294002 (PI3K inhibitor) for 6 days. Ten ng/
ml Activin A (Prepotech) was added for two days starting on day 2. To induce
metanephric mesenchyme (MM) specification and renal progenitors phenotype by
day 6 up to 19 the medium was replaced with fresh basal medium containing
nephrogenic factors: 50 ng/ml BMP7 (Prepotech), 10 ng/ml FGF2 and 15 ng/ml
GDNF (Abcam). The medium was changed every 2 days.
RNA Isolation and real-time PCR assays. Total RNA was isolated by RNeasy plus
Mini Kit (Qiagen). First-strand cDNA was produced from 2 mg total RNA using
SuperScript II First-Strand Synthesis Systems Kit (Invitrogen) using a mixture of
oligo-dT and random hexamers oligonucleotides following manufacturer’s
instructions. The pluripotency of human iPSCs clone IV was evaluated by TaqMan
gene expression assay (Life Technologies) using predesigned probes for pluripotent
and undifferentiated gene markers (Supplementary Table 1) according to the
supplier’s instructions. RNA from commercially available human iPSCs was used as
reference sample and the gene expression level was normalized to RAF1
housekeeping gene.
For gene expression analysis in renal induction experiments TaqMan Array
Human Endogenous Control Plate (Life Technologies) was used in order to evaluate
the best housekeeping gene and ELF1 gene was chosen to normalize the gene
expression level. Real-time PCR assays were performed using Power Syber Green
PCR master mix (Life Technologies). The primers employed are listed in
Supplementary Table 2. The DDCt technique was used to calculate cDNA content in
each sample using the cDNA expression of the pluripotent state (d0) as a calibrator.
The experiments were performed in triplicate and the results were expressed as mean
6 SD.
Cell immunostaining. Cells were fixed in 4% PFA in PBS for 30 min at room
temperature. When appropriate, cells were permeabilized in 0.5% Triton X-100 for
30 min at room temperature followed by incubation in blocking solution (5% BSA).
The primary antibodies were diluted according to manufacturer’s recommendations
and incubated overnight at 4uC, followed by incubation with the appropriate
secondary antibody for 1 h at room temperature. Primary antibodies included anti-
OCT4 (Santa Cruz); anti-NANOG (Santa Cruz); anti-TRA-1-60 (Millipore); anti-
TRA-1-81 (Millipore); anti-SSEA3 (Santa Cruz); anti-SSEA4 (Santa Cruz); anti-AFP
(Santa Cruz); anti-a-SMA Cy3- conjugated (Sigma); anti-b III Tubulin Alexa Fluor
488- conjugated (Millipore), anti-T (Abcam), anti-Osr1 (Santa Cruz), anti-Lhx1
(Abcam), anti-Wt1 (R&D System), anti-Pax8 (Novus biologicals), anti-Six2
(Proteintech, Abnova), anti-Pax2 (Invitrogen), anti-Sall1 (R&D System), anti-CD24
(Santa Cruz), anti-NCAM (Millipore), anti-AQP1 (Abcam), anti-GGT1 (Santa
Cruz), anti-Claudin1 (Thermo Scientific), anti-Pax6 (Novus biologicals) and anti-
Nkx2.5 (Thermo Scientific). For CD133 staining, cells, after fixing, were blocked with
1.5% normal goat serum for 1 h at RT and incubated with anti-CD133 antibody
(Miltenyi Biotech, AC133/1) for 1 h at 37uC. Subsequently the cells were washed
twice with 0.1% Tween 20 and twice with PBS. Appropriate Alexa Fluor 546 and
Alexa Fluor 488 secondary antibodies (Molecular Probes) were used followed by
nuclear counterstaining with 49,6-diamidino-2-phenylindole (DAPI) for 10 minutes
at room temperature. Images (representative of n 5 3 experiments) were taken by
Apotome Axio Imager Z2 (Zeiss).
Flow cytofluorimetric analysis. TRA-1-81 expression was performed by flow
cytometer FACs Canto (BD Bioscience). Cells were detached and incubated for
30 min with 1% BSA. Cells were then stained for 1 h with TRA-1-81 (Abcam),
primary antibody diluted according tomanufacturer’s recommendations followed by
the appropriate secondary antibody.
In vivo experiments. Animal care and treatment were in accordance with
institutional guidelines in compliance with national (D.L. n.116, G.U., suppl 40, 18
February 1992, Circolare No. 8, G.U., 14 July 1994) and international laws and
policies (EEC Council Directive 86/609, OJL 358, Dec 1987; NIH Guide for the Care
and Use of Laboratory Animals, U.S. National Research Council, 1996). Animal
studies were submitted to and approved by the Institutional Animal Care and Use
Committee of ‘‘Mario Negri’’ Institute (Milan, Italy). Animals were housed in a
constant temperature room with a 12:12-h dark-light cycle and fed a standard diet.
Cisplatin-induced AKI mouse model and iPSC injection. Two-month-old female
NOD-SCID mice (Charles River Italia S.p.a.) received a subcutaneous injection of
13.9mg/kg cisplatin (Ebewe Italia Srl) and after 24 h were divided into three groups
receiving an intravenous injection, through the tail vein, of saline, undifferentiated
iPSCs or iPSC-derived RPCs (5 3 105 cells/mouse). In selected experiments, iPSC-
derived RPCs have been pre-labeled with cell tracker PKH26 (Sigma Aldrich)
following manufacturer’s instructions. Mice were sacrificed 4 days after cisplatin and
kidneys were used for histology and immunohistochemistry. Human cell
engraftment in kidney, liver, lung, heart and spleen was evaluated in cisplatin-treated
www.nature.com/scientificreports
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mice 24 hours after infusion of iPSCs or iPSC-derived RPCs. Renal function was
assessed as blood urea nitrogen (BUN) by the Reflotron test (Roche Diagnostics
Corporation). BUN levels exceeding 30 mg/dl were considered abnormal. To
evaluate any possible cell maldifferentiation or tumor formation, an additional group
of cisplatin-mice injected with iPSC-derived RPCs (n 5 3 animals) were sacrificed 8
weeks after cisplatin injection and kidney, heart, liver and lung were examined.
Normal, untreated mice served as controls.
Immunohistochemical analysis of tissues from kidney and other organs. Kidney
samples were fixed in Duboscq-Brazil and paraffin sections were stained with
hematoxylin and eosin, or periodic acid-Schiff’s reagent (PAS). Luminal hyaline casts
and tubular necrosis (denudation of tubular basement membrane) were assessed in
non-overlapping fields (up to 28 for each section) (40X, high power field, HPF).
To identify human iPSCs in murine renal tissues, acetone-fixed cryosections were
incubated with anti-human nuclei antigen (HNA) Alexa Fluor 488 (Millipore) or anti
human mitochondria (Millipore) primary antibody diluted according to manufac-
turer’s recommendations followed by Cy3-conjugated donkey anti-mouse antibody
(Jackson Laboratories). Sections were then co-stained with Rhodamine or FITC-
labeled wheat germ agglutinin and DAPI. Fluorescence was examined by Apotome
Axio Imager Z2 (Zeiss). The percentage of HNA positive cells per field was calculated
by counting HNA- positive cells on total DAPI positive nuclei in 20 non-overlapping
random areas per section. Human iPSC-derived RPCs, pre-labeled with PKH26, have
been studied in PLP fixed renal sections co-stained with anti-AQP1 antibody
(Abcam) followed by the appropriate Cy5-conjugated secondary antibody, FITC-
WGA lectin and DAPI staining. In additional experiments, to identify human cells in
distal tubuli and collecting ducts, sections have been stained with anti PNA-lectin
(Vector Laboratories) or anti-AQP3 antibody (AbCam), respectively.
Duboscq-Brazil-fixed, paraffin-embedded kidney sections (3 mm) were used to
study immunophenotype of human cells in the kidney of cisplatin-injected mice.
Briefly, sections were deparaffinized, rehydrated, and then incubated for 30 minutes
with 0.3% H2O2 in methanol to quench endogenous peroxidase. After antigen
retrieval and blocking with 1% bovine serum albumin (BSA), serial sections were
incubated with the primary antibodies rabbit AQP1 (Santa Cruz) or anti human
mitochondria (Millipore). Then, specimens were incubated with the biotinylated
species-specific secondary antibodies, avidin-biotin peroxidase complex solution,
and developed with diaminobenzidine. Slides were finally counterstained with
hematoxylin, dehydrated in graded alcohols, mounted and observed by light
microscopy (ApoTome Axio Imager Z2, Zeiss). Negative controls were obtained by
omitting the primary antibody on adjacent sections. Human kidney tissues have been
used as positive controls for human mitochondria staining.
In order to study cell proliferation of human iPSC-derived RPCs in the kidney 4
days after cisplatin treatment, acetone-fixed cryosections were incubated with anti-
HNA-Alexa fluor 488 (Millipore) and anti-Ki67 (Abcam), followed by the appro-
priate Cy5-conjugated secondary antibody, rhodamine-labeled WGA lectin and
DAPI. Cell proliferation has been quantified as the number of Ki-67-positive cells/
HPF (25–30 fields/section, n 5 4 animals/group).
Human iPSCs and iPSC-derived RPC engraftment was analyzed in formalin-fixed,
paraffin-embedded liver, lung, heart and spleen. Three sections for each animal (n 5
3/group) have been stained with anti-human mitochondria (Abcam) as previously
described. RPC engraftment was quantified as the number of human mitochondria-
positive cells/HPF (20–35 fields/section).
Statistical analysis. Results are expressed as mean 6 SEM. Data were analyzed by
ANOVA followed by Tukey-Cicchetti test for multiple comparisons or t test for
unpaired data, as appropriate. P , 0.05 was considered to represent statistically
significant differences.
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